Abstract
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) that afflicts over 2 million people worldwide. On the basis of the temporal course of disease, MS can be subdivided into three clinical groups: relapsing remitting MS (RR-MS), secondary progressive MS and primary progressive MS. There is a high degree of clinical diversity within these subgroups. The pathogenesis of MS in most patients is likely to result from autoreactive, activated CD4+ T cells moving from the periphery across the blood brain barrier into the CNS. Most therapeutic agents used in MS (e.g. immunosuppressive and immunomodulatory drugs and cell cycle interruption drugs) are only used for RR-MS. These treatments show some efficiency in lessening the relapse rate in RR-MS and time to progression, but cannot cure MS. Thus, there is a need for new efficient treatments for all types of MS. An increasing number of studies indicate that nuclear factor-κB plays an important role in controlling expression of genes relevant to the pathogenesis of autoimmunity. Genetic factors related to NF-κB may also be determinants of MS susceptibility, as polymorphisms in the molecules involved in regulation of the NF-κB signal transduction pathway differ between RRMS and progressive MS. Herein, the role of NF-κB in MS will be reviewed and its potential as a new therapeutic target in MS will be considered and compared with existing treatments.
Keywords: Multiple sclerosis, NF-κB, IκB, IKK, autoimmunity, therapy, therapeutic intervention
CNS & Neurological Disorders - Drug Targets
Title: NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
Volume: 7 Issue: 6
Author(s): J. Yan and J. M. Greer
Affiliation:
Keywords: Multiple sclerosis, NF-κB, IκB, IKK, autoimmunity, therapy, therapeutic intervention
Abstract: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) that afflicts over 2 million people worldwide. On the basis of the temporal course of disease, MS can be subdivided into three clinical groups: relapsing remitting MS (RR-MS), secondary progressive MS and primary progressive MS. There is a high degree of clinical diversity within these subgroups. The pathogenesis of MS in most patients is likely to result from autoreactive, activated CD4+ T cells moving from the periphery across the blood brain barrier into the CNS. Most therapeutic agents used in MS (e.g. immunosuppressive and immunomodulatory drugs and cell cycle interruption drugs) are only used for RR-MS. These treatments show some efficiency in lessening the relapse rate in RR-MS and time to progression, but cannot cure MS. Thus, there is a need for new efficient treatments for all types of MS. An increasing number of studies indicate that nuclear factor-κB plays an important role in controlling expression of genes relevant to the pathogenesis of autoimmunity. Genetic factors related to NF-κB may also be determinants of MS susceptibility, as polymorphisms in the molecules involved in regulation of the NF-κB signal transduction pathway differ between RRMS and progressive MS. Herein, the role of NF-κB in MS will be reviewed and its potential as a new therapeutic target in MS will be considered and compared with existing treatments.
Export Options
About this article
Cite this article as:
Yan J. and Greer M. J., NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets 2008; 7 (6) . https://dx.doi.org/10.2174/187152708787122941
DOI https://dx.doi.org/10.2174/187152708787122941 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Cell Products for Treatment of Autoimmune Neuroinflammatory Diseases
Current Medicinal Chemistry Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Mediterrranean Diet and Health Biological Importance of Olive Oil
Current Pharmaceutical Design Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antibody - Fc Receptor Interactions in Antimicrobial Functions
Current Immunology Reviews (Discontinued)